Ubiquitous as they may be today, the origin of the Christmas tree is unknown to most. The tradition of decorating a tree, usually an evergreen […]

The post Agustín Stahl: Scientist Who Introduced the “Arbol de Navidad” (Christmas Tree) to Puerto Rico appeared first on Smithsonian Insider.

UK-based automotive payment provider Auto Service Finance has secured a debt and...

One of the nation’s largest surveys of crime victims is likely undercounting incidences of rape and sexual assault, making it difficult to ensure that adequate law enforcement resources and support services are available for victims, says a new report by the National Research Council.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome -- commonly referred to as ME/CFS -- is a legitimate, serious, and complex systemic disease that frequently and dramatically limits the activities of affected individuals, says a new report from the Institute of Medicine.

Weather and environmental forecasts made several weeks to months in advance can someday be as widely used and essential as current predictions of tomorrow’s weather are, but first more research and sustained investment are needed, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Increasing energy demands and expanding industrial and agricultural activities worldwide are changing the composition of the atmosphere and contributing to major global challenges like climate change and air pollution. The study of atmospheric chemistry plays a key role in understanding and responding to these challenges, and research in this field has been successful in guiding policies to improve air quality in urban areas and reduce acid rain and stratospheric ozone depletion.

The end of a roadside guardrail must be designed so that it is not a hazard to occupants of a vehicle striking it and so that it absorbs energy in a crash and redirects the vehicle into a safe trajectory.

The U.S. Department of the Interior’s Bureau of Safety and Environmental Enforcement has ordered the National Academies of Sciences, Engineering, and Medicine to suspend all work on a study to review and update the bureau’s offshore oil and gas operations inspection program to enhance safety.

Current federal safety regulations for small distribution systems used for propane and other liquefied petroleum gases (LPGs) should be improved for clarity, efficiency, enforceability, and applicability to risk, says a new reportfrom the National Academies of Sciences, Engineering, and Medicine.

For his pioneering role in national health policy and health services research, the National Academy of Medicine today announced Stuart Altman is the recipient of the 2018 Gustav O. Lienhard Award for Advancement of Health Care.

A new report from the National Academies of Sciences, Engineering, and Medicine presents a research roadmap to address gaps and uncertainties in estimating the impacts of proposed changes in truck size and weight limits -- the regulations that set the maximum weights, lengths, and numbers of trailers allowed for trucks on U.S. highways.

Higher education leaders, policymakers, and the private sector should take a range of actions to strengthen STEM programs and degree attainment in the nation’s Minority Serving Institutions (MSIs), says a new report from the National Academies of Sciences, Engineering, and Medicine.

Along with participation in the International Thermonuclear Experimental Reactor (ITER) project – a large, international burning plasma experiment – the U.S. Department of Energy (DOE) should start a national program of accompanying research and technology to build a compact pilot plant that produces electricity from fusion at the lowest possible capital cost, says a new report from the National Academies of Sciences, Engineering, and Medicine.

NASA’s investment in new instruments to analyze extraterrestrial samples is insufficient to provide for replacement of existing instruments, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Biotechnology has the potential to be a part of the solution in protecting forest trees against destructive pest and disease outbreaks

The nation’s highways and roads connect almost 330 million Americans and are important to both commerce and national security. Two-thirds of total passenger travel in the country moves along this vast network of roads, as does 60 percent of the weight and almost three-quarters of the value of total U.S. freight transported.

Rwanda’s Human Resources for Health (HRH) Program – funded in part by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) from 2012 to 2017 – more than tripled the country’s physician specialist workforce and produced major increases in the numbers and qualifications of nurses and midwives, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Researchers are scrambling to find effective treatments for COVID-19, which has infected more than 1 million people around the word.

State and local leaders break ground at a Louisville, Ky., coal-burning power plant in November 2012.; Credit: Dylan Lovan/AP

California State Senator Kevin de Leon says he’ll introduce legislation next month to get the state’s public employees retirement system off of coal.

Just back from ho-hum international talks in Lima, where he was a member of California's delegation, de Leon spoke at a conference in Oakland. It was sponsored by NextGen Climate, a nonpartisan group founded by billionaire philanthropist Tom Steyer to raise the profile of climate change among issues in the U.S. political debate.

“With coal power in retreat, and the value of coal dropping, it’s time for us to lead again in moving our massive state portfolios to lower carbon investments,” De Leon said. “Divestment is about matching your values with your investment strategy — and still seeing positive financial returns… California has prohibited its energy companies from buying or importing coal power, and state funds should match that.”

De Leon proposes to divest the nation’s two largest public pension funds from coal. The California Public Employees Retirement System, or CALPERS, is the nation’s largest, controlling about $295 billion as of the end of September.  The California School Teachers Retirement System is a sister fund for pensions of nearly 850,000 California teachers. CALSTRS controls another $187.1 billion dollars in potential investments.

Burning coal for energy is a major source of greenhouse gases that are warming the planet. The move would lend momentum to a divestment movement already underway, largely targeted at investment funds belonging to colleges and universities nationwide.

Stanford and Pitzer College in Claremont are among a dozen universities that have pulled investments out of the coal industry. But others, including the University of California have refused. 

This content is from Southern California Public Radio. View the original story at SCPR.org.

His expression said it all.  KPCC Director of On-Air Fundraising Rob Risko walked into my studio about 10:45 a.m. to update me on where we stood with our Fall member drive.  I knew we had a $10,000 challenge that had started first thing in the morning, but didn't have any idea how far behind we had fallen in reaching the required 1,000 member threshold.

 Rob gave it to me straight -- we had to attract well over 500 members during "AirTalk" to meet the challenge.  I knew that was nearly impossible during a full two-hour show, let alone one that would be significantly pre-empted by the President's news conference.  Regardless, I knew we had to do our best and hope our listeners would contribute in a record-setting way.  Boy, did they.

We didn't start our show until 11:25 a.m., following the news conference.  Right off the bat the phones started ringing and the KPCC website starting humming.  The volume of member contributions stayed high with only a few exceptions.  There were times we could barely keep track of how many members were coming in.  It was one of the most exciting and rewarding experiences I've had in all my years hosting "AirTalk."

I've been on a high all afternoon thinking about how commited our listeners are to the mission of KPCC.  You've made me very happy, and very proud of our audience.  Thank you for a wonderful show of support.  I will long remember this day.

By the way, we set a fundraising record for "AirTalk" with today's show.  We're still tallying it all up.  I'll have the totals for you tomorrow morning at 11.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Frank Romero with one of his French paintings, in his home in the South of France. But every year, he and his wife Sharon throw a big studio sale for Christmas, and you're invited.; Credit: John Rabe

"Live! Life's a banquet and most poor suckers are starving to death!" - Auntie Mame.

Your calendar is filling up, but here are four holiday events you'll want to make room for:

Every year, pioneering Chicano artist Frank Romero and his wife Sharon throw a big studio sale that includes works by a wide group of artists, and a lot of food and drink. It's just as much a party as a sales event, and Frank and the other artists are always there to meet and greet. And now that the couple is spending more time at their home in France, it's a chance for their old friends to catch up with them, so who knows who you'll see from L.A.'s arts community.

RELATED: See Frank's new works - French scenes with an East LA flavor

The Romero Studio annual Christmas party and sale is Saturday, Dec. 6, 6-10pm; and Sunday, Dec. 7, 1-5pm, at Plaza de la Raza, Boathouse Gallery, 3540 North Mission Rd., LA CA 90031 (in Lincoln Park across from the DMV — which BTW is a very good DMV).

Then, on Sunday, Dec. 14, at 4:30pm,  it's the Advent Procession of Lessons and Carols, at St. James Episcopal Church, which a friend describes as "one of the truly beautiful choral events of the season," and the highlight of the Choir of St. James' season. It's free and it's at St. James' Episcopal Church in Koreatown (3903 Wilshire Blvd., Los Angeles 90010).
 

"Auntie Mame," the 1958 Rosalind Russell movie with more quotable quips than a weekend getaway with Oscar Wilde, has become something of a Christmas tradition. It's screening at the American Cinematheque's Egyptian Theatre on Wednesday, Dec. 17, at 7:30. As delightful as this movie is any day of the week on your TV at home, this is a film to be seen in 35mm with a theater full of people reacting to every bon mot and heart-touching moment.

GO INSIDE: The Disney Hall organ, "Hurricane Mama," turns 10

Last year, my husband and I blindly went to Disney Hall for the Holiday Organ Spectacular. We expected some music and a little fun. But it really was spectacular. It's back this year, on Friday, Dec. 19, with organist David Higgs leading the evening from the console of Hurricane Mama.

If you've never seen or heard the organ in person, this is a great evening because Higgs — a teacher as well as master organist — gives you a guided tour of every stop, and every mood the organ can produce, from cathedral-loud to country-church-quiet. At the end of the night, he breaks the audience into parts to sing "The Twelve Days of Christmas," and you may sing as loud as you like.

These are just a few curated selections, but they're just the tip of the iceberg in Southern California; please make your own holiday event recommendations in the comments below. 

This content is from Southern California Public Radio. View the original story at SCPR.org.

People wait in line to receive food at a food bank on April 28, 2020 in the Brooklyn borough of New York City.; Credit: Spencer Platt/Getty Images

United States unemployment has reached record numbers with more than 30 million Americans applying for benefits in just six weeks, according to the Guardian. Economists expect the labor market to take another unprecedented blow for the month of April. 

Roughly one in five people in California's workforce have applied for initial unemployment insurance benefits, including a "staggering" 37% of workers with no more than a high school diploma. That's the estimate of a  study from the California Policy Lab that analyzed unemployment insurance claims from March 15-April 11. According to the California Economic Development Department (EDD), L.A. County's unemployment rate jumped from 4.3% in February to 6.3% in March. The state of California launched its Pandemic Unemployment Assistance program last week, giving many independent contractors their first chance to apply for benefits.But applicants have had a tough time getting through the system because of technical difficulties with the state's website.

Today on AirTalk we check in on unemployment in the state. Plus, some people are making more money through unemployment benefits than when they were working. We talk to the writer of a recent Wall Street Journal piece that looks at the challenges that presents for businesses as states look to slowly reopen. Do you have questions about unemployment across the state or the application process? Join the conversation by calling 866-893-5722. 

With files from LAist. Read more from David Wagner here. 

Guests:

Eric Morath, labor economics and policy reporter for the Wall Street Journal, he’s based in Washington D.C.; he tweets @EricMorath

George Warner, attorney in the Wage Protection Program at Legal Aid at Work, a San Francisco based nonprofit law firm that assists low-income, working families throughout California; he tweets @readerznriderz

This content is from Southern California Public Radio. View the original story at SCPR.org.

Attorney General William Barris pictured at a coronavirus task force meeting at the White House on March 23. The Justice Department is looking to crack down on coronavirus-related fraud.; Credit: Alex Brandon/AP

The coronavirus pandemic has brought out the good side of many Americans, but certainly not all Americans. Officials say that fraud related to COVID-19 — like hoarding equipment, price gouging and hawking fake treatments — are spreading as the country wrestles with the outbreak.

"It's a perfect ecosystem for somebody like a fraudster to operate in," said Craig Carpenito, the U.S. attorney for New Jersey and the head of the Justice Department's COVID-19 price gouging and hoarding task force.

"People want to believe that there's a magic pill that they can take or that if they buy a certain kind of mask or a certain kind of protective gear that it's going to protect them and their families," he said. "That creates opportunities for the types of people that prey upon scared people. They prey upon their fear."

A month ago, Attorney General William Barr instructed federal prosecutors around the country to aggressively investigate and prosecute scams and other crimes related to the COVID-19 pandemic. He also created the price gouging and hoarding task force and put Carpenito in charge of it.

From that perch, Carpenito has one of the best views of virus-related crime nationwide.

"Instead of seeing that tremendous support from all aspects of society, we're still seeing that sliver, that that dark underbelly, that small percentage of folks who instead of putting the interests of the country and support for those medical professionals that are putting themselves at risk in the forefront, they're finding ways to try and take advantage of this situation and illegally profiteer from it," he said. "And it's despicable."

The most prevalent kind of fraud that federal authorities are seeing at this point, he and others say, is tied to personal protective equipment like N95 masks, gloves or face shields.

In one notable case, prosecutors brought charges against a Georgia man, Christopher Parris, for allegedly trying to sell $750 million worth of masks and other protective equipment to the Department of Veterans Affairs but with a sizable advance payment.

The problem, prosecutors say, is the masks and other items didn't exist, at least not in the quantities Parris was offering.

Steven Merrill, the head of the FBI's financial crimes section, says the bureau refers to these sorts of operations as advance-fee schemes.

"We're getting many complaints that different entities are entering into these agreements, paying money upfront, sometimes hundreds of millions of dollars, and may or may not get any masks or other PPE ordered at all," Merrill said. "So our guidance to the public is to please be wary of these frauds and solicitations."

Other problems, such as hoarding and price gouging, can arise even when the medical gear does exist.

The FBI is trying to identify individuals who are stockpiling protective equipment and trying to sell it at exorbitant markups, sometimes 40 to 70 times the value, Merrill said.

A few weeks ago, the FBI seized nearly 1 million respirator masks, gloves and other medical gear from a Brooklyn man who was allegedly stockpiling them and selling them to nurses and doctors at what officials say was around a 700% markup.

The man, Baruch Feldheim, has been charged with lying to the FBI about price gouging. He's also been charged with allegedly assaulting a federal officer after he coughed on agents and claimed he had COVID-19.

The confiscated items, meanwhile, have been distributed to medical workers in the New York area.

Carpenito said the Justice Department has more than 100 investigations open into price gouging. It has hundreds more, he said, into other crimes tied to the pandemic, including fake treatments and cures.

In one case out of California, prosecutors charged a man who was allegedly soliciting large investments for what he claimed was a cure for COVID-19.

"He was doing so by broadcasting this scheme via, notably, YouTube, where had thousands of hits and views," Merrill said.

In a separate case out of Florida last week, the Justice Department got a court order to stop a Florida church from selling on its website an industrial bleach that was being marketed as a miracle treatment for the virus.

To be clear, the Centers for Disease Control and Prevention says there is no cure at this point for the virus.

More than a month into this crisis, there's no sense COVID-related crime is going to slow down.

In fact, Carpenito and Merrill say that with the massive $2 trillion economic relief package beginning to be doled out, they expect to see even more fraud in the weeks and months ahead.

"What we're worried about is that not only do we have these existing conditions, but we are awaiting — like everybody in the country — the arrival of $2 trillion to hit the streets," Merrill said. "And anytime there's that much money out there, you can just multiply the amount of frauds that are going to take place. So we're preparing for many more complaints to come in and new schemes to arrive on a daily basis."

This content is from Southern California Public Radio. View the original story at SCPR.org.

The Asian Garden Mall in Westminster, where voters will make a choice about whether to recall city leaders.; Credit: Dorian Merina/KPCC

Voters in Westminster will decide this spring whether to recall its mayor and two city councilmembers. The Orange County Registrar of Voters has signed off on petitions for a recall election.  

This content is from Southern California Public Radio. View the original story at SCPR.org.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Director Eliza Hittman on the set of her film "Never Rarely Sometimes Always".
; Credit: Focus Features/Never Rarely Sometimes Always (2020)

The film “Never Rarely Sometimes Always” was slated for a theatrical release in March, but due to COVID-19 screenings were postponed. Instead, the film is out on digital this week, currently sporting a 98 percent rating on Rotten Tomatoes and receiving critical acclaim both here on FilmWeek and nationwide as one of the best films of 2020 so far.

Writer-director Eliza Hittman’s third feature-length film is about two teenage girls Skylar (Talia Ryder) and Autumn (Sidney Flanagan) from rural Pennsylvania who travel to New York City for medical help after an unplanned pregnancy. Hittman says the idea for the film came to her when she read in a book about how some women in Ireland, which up until recently had very strict laws against abortions, would travel from Ireland to London in 24 hours just to get a procedure. It struck her as worthy of a screenplay, and the idea was born. As part of her research for the film Hittman went to a small coal-mining community in rural Pennsylvania and, even though she wasn’t pregnant, visited pregnancy centers, got tested, and talked with women getting treatment and counseling so she could, as she says, “write the scenes with credibility.”

Today on FilmWeek, we’ll air “The Frame” host John Horn’s interview with “Never Rarely Sometimes Always” director Eliza Hittman where the two discuss how Hittman came up with the idea for the film, her journey to rural America to find out what visiting pregnancy centers there is like, and how that informed the way she conceived and wrote the film.

Guest:

Eliza Hittman, writer and director of “Never Rarely Sometimes Always”

This content is from Southern California Public Radio. View the original story at SCPR.org.

Saltmarsh restoration can contribute to a range of ecosystem services but, according to new research, the effectiveness depends on previous land use. To optimise restoration, more research is needed on the effects of previous land disturbance on the delivery of ecosystem services and the relationships between physical, biogeochemical and ecological processes.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Finding affordable apartments is especially tough in Los Angeles, where 52 percent of people are renters, according to a new study.; Credit: Justin Sullivan/Getty Images

You need to earn at least $33 an hour — $68,640 a year — to be able to afford the average apartment in Los Angeles County, according to Matt Schwartz, president and chief executive of the California Housing Partnership, which advocates for affordable housing. 

That's more than double the level of the highest minimum wage being proposed by Mayor Eric Garcetti, which he argued would make it easier for workers to afford to live here. “If we pass this, this will allow more people to live their American Dream here in L.A.," Garcetti proclaimed when he announced his plan to raise the minimum wage to $13.25 by 2017. 

The $33 an hour figure is based on the average L.A. County apartment rental price of $1,716 a month, from USC's 2014 Casden Multifamily Forecast. An apartment is considered affordable when you spend no more than 30 percent of your paycheck on rent.

To earn $33 an hour or more, you'd need to have a Los Angeles job like one of the following occupations: 

• Marketing manager: $66,538 (average in L.A., according to Payscale.com)
• LAUSD teacher: $70,000 (average salary, according to LAUSD)
• Software engineer: $82,669 (average according to Payscale.com)
• Lawyer: $104,249 (average according to Payscale.com)

But many occupations typically earn far below that $33 an hour threshold in L.A. County, according to the California Housing Partnership:

• Secretaries: $36,000 ($17 an hour)
• EMT Paramedics: $25,00 ($12 an hour)
• Preschool teachers: $29,000 ($14 an hour)

That's why L.A. residents wind up spending an average of 47 percent of their income on rent, which is the highest percentage in the nation, according to UCLA's Ziman Center for Real Estate.

Naturally, people who earn the current California minimum wage of $9 an hour ($18,720 a year) would fare even worse in trying to afford an average apartment.

Raising the minimum wage to $13.25 would equal a $27,560 salary; raising it to $15.25 an hour totals $31,720 a year.

What about buying a home?

In order to afford to purchase the median-priced home in Los Angeles, you'd need to earn $96,513 a year, according to HSH.com, a mortgage information website. 

The median home price in Los Angeles is $570,500, according to the real estate website, Trulia.com.

But consider that the median income in Los Angeles is about half that: $49,497, according to census numbers from 2009-2013.

So it's no surprise that Los Angeles has been rated as the most unaffordable city to rent in America by Harvard and UCLA. 

The cost of housing has gone up so much that even raising the minimum wage to $15.25 an hour – as some on the city council have proposed doing by 2019– would not go very far in solving the problem.

“Every little bit helps, but even if you doubled the minimum wage, it wouldn’t help most low-income families find affordable rental housing in Los Angeles,” said Schwartz.

What percentage of your income to you spend on housing in Los Angeles? Let us know in the comments, on our Facebook page or on Twitter (@KPCC). You can see how affordable your neighborhood is with our interactive map.

An earlier version of this story incorrectly calculated the hourly pay rate, based on the estimated $68,640 annual pay needed to afford the average rent in L.A. County. KPCC regrets the error.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports   04/28/2020

News Flash: On May 7, CloudMD announced that it is partnering with IDYA4 Corp. for it to resell the health technology firm's Livecare technology in the U.S.. Read more here.

News Flash: On May 4, CloudMD announced that it is partnering with Save-On-Foods grocery stores and Pure Integrative Pharmacy to pilot on demand, integrated virtual patient care through telemedicine kiosks placed in pharmacies' existing consult rooms. Read more here.

As people are avoiding going to doctor's offices and hospitals during the coronavirus pandemic, telemedicine has taken off. Two investment professionals, Bruce Campbell and Keith Schaefer, have called CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE), a small-cap Canadian telemedicine firm, a top pick.

Bruce Campbell, founder and portfolio manager of Stonecastle Investment Management, spoke about CloudMD on April 27 on BNN:

"The first top pick is CloudMD Software, a technological medical play. We've tried to look at opportunities that are really going to be able to take advantage of Covid and this is one of the ones that we think is; what they do is telemedicine.

"The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now." - Keith Schaefer

If you look back at a year ago, where everyone had to go to the doctor, and now all of the different provinces have opened up billing codes, so that now we don't have to go into a doctor's office. We can do a virtual doctor's visit and the doctor gets paid just like they do with an in-house appointment. Obviously with everything that has happened with this crisis, people really don't want to go into a doctor's office and they need a prescription renewal or something like that.

If you look at CloudMD's peers in the U.S., there is a company called Teladoc, which is a big U.S. company that does the same thing. Obviously, the size of the market is different, but the multiple it trades at is multiple times higher than where CloudMD is.

CloudMD is just starting to gain adoption. They started off here in BC, they have moved to Ontario, and they are going to be rolling out really across the country, so tons of opportunity for a company like this. They will probably change the way that we view our doctor and our healthcare visits going forward."

Keith Schaefer, editor and publisher of Oil & Gas Investments Bulletin, is also following CloudMD, and wrote:

"An entirely new—and highly profitable—industry is being borne out in 2020—TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play TeleHealth. It's growing quickly with over 100,000 patients registered on its app and over 3000 doctors in 8 provinces in its Electronic Medical Records—EMR—system. It has MULTIPLE revenue streams and it just moved into Canada's largest market—Ontario—setting up an even faster growth rate.

The recent spread of coronavirus is only accelerating this. Covid-19 has forever changed how we all will think about visiting a hospital or seeing our doctor. We really don't want to do that at all, if possible. It will have a very positive and long lasting impact on TeleHealth.

TeleHealth companies in Canada are getting paid more money for services than bricks-and-mortar clinics, and have a fraction of the costs. Doctors want more of it, patients want more of it, government wants more of it—and the Market REALLY wants more of it. Everybody wins here; there is no downside.

The rapid scale-up and profitability is key for investors.

CloudMD is established, growing quickly and trading at a fraction of its peers. The average multiple of competitors in the sector trade at 5-7x revenue, and CloudMD is trading way below that at 2.5x per revenue. But realize that the Canadian use of telemedicine is still just a fraction of where it is in the U.S—so the quick, early upside is even bigger.

The market desperately wants to own TeleHealth right now. I see CloudMD as the best way to do that in the junior sector (where the leverage is!).

For this stock to have a major run all that needs to happen is for institutional investors to wake-up to the fact that the company exists. That's happening now with the company entering the province of Ontario—which has 14.5 million people—over one-third of Canada's population.

CloudMD is a fully integrated health care company—kind of like a hospital-in-the-sky. They do have five bricks-and-mortar clinics, but they also own their own EMR—Electronic Medical Records—system that operates in eight provinces and is used by over 3,000 doctors and is supported by an in-house 25 person development team. They have their own CloudMD app—which has over 100,000 registered patients already.

The EMR gives CloudMD a recurring monthly revenue stream, which The Street loves. The app gives them high-margin fees from doctors, specialists and groups like massage therapists & counselors. These people are revenue, not costs. As I said, full hospital-in-the-sky. Multiple revenue sources with lower costs.

To schedule a virtual doctor's appointment all that a patient has to do is download the free CloudMD app and then arrange an appointment with one of the doctors. There is zero charge for the patient and they can see a doctor very quickly.

CloudMD can scale up the number of patients VERY quickly—and they are. Every aspect of healthcare that's very fractured and disjointed will now be in the one CloudMD ecosystem.
Everyone wins with this system. Patients, doctors, the medical system, society, even investors. Everyone.

Doctors who have signed up with CloudMD work remotely from home or wherever they are (like their winter home down south). The rapid scale-up potential excites me. CloudMD can add in unlimited number of doctors and patients—so it has a virtually unlimited ability to scale quickly with little incremental cost.

Profit margins are wide and there is no cap on the number of customers that can be handled.

After a patient has an appointment, CloudMD bills the government directly just like every bricks-and-mortar clinic in Canada does. CloudMD records 100% of the revenue and gets to keep 30% of the billing for every patient that is seen through telemedicine, which is actually 10% more than what a bricks-and-mortar clinic receives. That is because the governments are trying to push TeleHealth. The doctor gets the other 70% and doesn't have to deal with any headaches of commuting or running a business.

Without the overhead of a bricks-and-mortar clinic, AND more revenue, CloudMD will be much more profitable than traditional healthcare stocks. Faster scale, more cash flow. And they just entered Canada's largest market. This is the right stock in the right market at the right time. That's the great thing about this business model. It's very scalable, very easy, and it grows very quickly.

CloudMD has been growing its recurring SAAS (Software-as-a-Service) revenue by 30% YoY with its EMR system. But this year the company is expecting that doctor growth to be much much higher—with a new full time sales team and the coronavirus pandemic. SaaS revenue is highly lucrative!

The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now."

Read Keith Schaefer's entire article here.

Watch Bruce Campbell of StoneCastle Investments share his top picks: CloudMD, Lightspeed and Viemed.

Disclosure:
1) Keith Schaefer: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: CloudMD. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: CloudMD. My company has a financial relationship with the following companies mentioned in this article: None. Additional disclosures are listed below.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with CloudMD. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of CloudMD. Please click here for more information.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of CloudMD, a company mentioned in this article.

Additional Disclosures